Thursday 5 February 2015

Ebola Virus Disease

Ebola Virus Disease
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans.EVD outbreaks have a case fatality rate of up to 90%.EVD outbreaks occur primarily in remote villages in Central and West Africa, near tropical rainforests. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola virus.

Ebola first appeared in 1976 in two simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter was in a village situated near the Ebola River, from which the disease takes its name. Although non-human primates have been a source of infection for humans, they are not thought to be the reservoir but rather an accidental host like human beings.

Transmission

Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. In Africa, infection has been noticed among those handling infected chimpanzees, gorillas, fruit bats, monkeys, forest antelope found ill or dead or in the rainforest. Ebola then spreads in the community through human-to-human transmission, with infection resulting from direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated with such fluids. Men who have recovered from the disease can still transmit the virus through their semen for up to 7 weeks after recovery from illness.

Health-care workers have frequently been infected while treating patients with suspected or confirmed EVD when infection control precautions are not strictly practiced.


Signs and symptoms

EVD is a severe acute viral illness often characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. The incubation period, that is, the time interval from infection with the virus to onset of symptoms, is 2 to 21 days.



Diagnosis

Before a patient is diagnosed as infected with EVD, one should rule out malaria, typhoid fever, shigellosis, cholera, leptospirosis, plague, rickettsiosis, meningitis, hepatitis and other viral hemorrhagic fevers like dengue, yellow fever and kyasanur forest disease etc.


Vaccine and treatment

There is no specific treatment nor is any licensed vaccine for EVD available. Several vaccines are being tested, but none are available for clinical use. Severely ill patients require intensive supportive care. Patients are frequently dehydrated and require oral rehydration with solutions containing electrolytes or intravenous fluids.


Prevention and control

No animal vaccine against this is available. Routine cleaning and disinfection of pig or monkey farms (with sodium hypochlorite or other detergents) should be effective in inactivating the virus.

If an outbreak is suspected, the premises should be quarantined immediately. Culling of infected animals, with close supervision of burial or incineration of carcasses, may be necessary to reduce the risk of animal-to-human transmission. Restricting or banning the movement of animals from infected farms to other areas can reduce the spread of the disease.



As this viral outbreak in pigs and monkeys have preceded human infections, the establishment of an active animal health surveillance system to detect new cases is essential in providing early warning for veterinary and human public health authorities.



In the absence of effective treatment and a human vaccine, raising awareness of the risk factors for Ebola infection and the protective measures individuals can take is the only way to reduce human infection and death.


India and EBOLA

There is a risk the deadly virus could be imported into the country if the large population of Indians working in the four affected West African nations returns. There are nearly 45,000 Indian nationals living and working in Guinea, Liberia, Sierra Leone and Nigeria - where an outbreak of the disease has killed 932 people. While the risk of Ebola virus cases in India is low, preparedness measures are in place to deal with any case of the virus imported to India. Government has advised against all non-essential travel to the four countries, and authorities will screen travelers who originate from or transit through affected nations, and track them after their arrival in India.
The government will also set up facilities at airports and ports to manage travelers showing symptoms of the disease. State authorities have been instructed to designate hospitals with isolation wards for response to possible cases and to stock personal protective equipment.

H7N9 virus

H7N9 virus
Influenza A viruses are divided into subtypes based on two proteins on the surface of the virus: hemagglutinin (HA) and neuraminidase (NA). The avian influenza A(H7N9) virus designation of H7N9 identifies it as having HA of the H7 subtype and NA of the N9 subtype.
        Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. H7 influenza infections in humans are uncommon, but have been confirmed world-wide in people who have direct contact with infected birds. Reported in the Netherlands, Japan, and the United States. Until the 2013 outbreak in China, no human infections with H7N9 viruses have ever been reported.

Reported cases in 2014
      On January 21, 2014, it was reported that a 31-year-old thoracic surgeon had died four days previously, the first medical professional to die from H7N9 flu.
     On January 28 it was reported by the Chinese Center for Disease Control and Prevention that the virus had killed 20 people in China in 2014, with the total number of human infections at 102. That compares with 144 confirmed cases, including 46 deaths, in the whole of 2013.

Symptoms and treatment
     According to the World Health Organization, symptoms include fever, cough, and shortness of breath, which may progress to severe pneumonia. 
       The virus can also overload the immune system, causing what is known as a cytokine storm. Blood poisoning and organ failure are also possible. 
         Most of the patients with confirmed cases of H7N9 virus infection were critically ill and that approximately 20% had died of acute respiratory distress syndrome (ARDS) or multi organ failure.
Antigenic and genome sequencing suggests that H7N9 is sensitive to neuraminidase inhibitors, such as oseltamivir and zanamivir.

   The use of these neuraminidase inhibitors in cases of early infection may be effective, although the benefits of oseltamivir treatment have been questioned.
Mortality
     Keiji Fukuda, the World Health Organization's (WHO) assistant director-general for health, security and the environment, identified H7N9 as "...an unusually dangerous virus for humans." By early May the number of new cases sharply declined and the mortality rate remained at about 20%,however as seriously ill patients continued to die, the mortality rate rose to about 33% by July.

Vaccine
On October 26, 2013, Chinese scientists announced that they had successfully produced an H7N9 vaccine, the first influenza vaccine to be developed entirely in China.
 It was developed jointly by researchers from Zhejiang University, Hong Kong University, the Chinese Center for Disease Control and Prevention, China's National Institute for Food and Drug Control, and the Chinese Academy of Medical Science.
 A(H1N1)pdm09 vaccines [about 60% to 70% effectiveness], particularly with regard to vaccine efficacy in persons older than 65 years.